AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27483410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy
Number of subjects: 550
Study 25893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force-guided procedure (Group B)
Number of subjects: 70
Study 25893569 — intervention group
Group type: COMPARATOR
Intervention: Non-contact force-guided procedure (Group A)
Number of subjects: 70
Study 25893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 70
Study 23870712 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimode Comprehensive Tailored Information Package (MCTIP)
Number of subjects: 103
Study 23870712 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 103
Study 21430116 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 μg daily for 3 years)
Number of subjects: 819
Study 21430116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study 19880456 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Screening Scale
Number of subjects: 5169
Study 19880456 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening linked to treatment options via referral and follow-up
Number of subjects: 5169
Study 19880456 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice strategies for implementing screening
Number of subjects: 5169
Study 17112853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) after conversion from azathioprine (AZA)
Number of subjects: 169
Study 17112853 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI elimination or minimization
Number of subjects: 169
Study 14988972 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic electronic record preventive care reminder system
Number of subjects: 10
Study 14988972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 10
Study 11488741 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypospadias objective scoring evaluation (HOSE) system
Number of subjects: 20
Study 9707027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy only (chemo)
Number of subjects: 122
Study 9707027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and total body irradiation (chemo + TBI)
Number of subjects: 122
Study 7837149 — intervention group
Group type: EXPERIMENTAL
Intervention: CREST syndrome
Number of subjects: 34
Study 7837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse scleroderma
Number of subjects: 34
Study 7837149 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 3349312 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge resection/segmental phenolization combination treatment (WR/SP)
Number of subjects: 140
Study 3349312 — intervention group
Group type: COMPARATOR
Intervention: Wedge resection (WR)
Number of subjects: 140
Study 3349312 — intervention group
Group type: COMPARATOR
Intervention: Segmental phenolization (SP)
Number of subjects: 140
Study 31629355 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-Based Exercise Program (CB)
Number of subjects: 25
Study 31629355 — intervention group
Group type: COMPARATOR
Intervention: Home and Center-Based Exercise Program (H+CB)
Number of subjects: 25
Study 30041703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered Motivational Interviewing (MI) intervention
Number of subjects: 420
Study 30041703 — intervention group
Group type: COMPARATOR
Intervention: Physician Standard of Care (Control)
Number of subjects: 420
Study 28561039 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 89
Study 28561039 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 89
Study 28561039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength + endurance training
Number of subjects: 89
Study 28561039 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Number of subjects: 89
Study 26286872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.5 mg/kg)
Number of subjects: 82
Study 26286872 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate syrup (50 mg/kg)
Number of subjects: 82
Study 24185540 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 70
Study 24185540 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 70
Study 19778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit vessel angioplasty-only (COR group)
Number of subjects: 263
Study 19778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged revascularisation (SR group)
Number of subjects: 263
Study 19778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment of non-IRA (CR group)
Number of subjects: 263
Study 19055715 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct feeding on gametocyte carriers
Number of subjects: 372
Study 19055715 — intervention group
Group type: COMPARATOR
Intervention: Membrane feeding method
Number of subjects: 372
Study 16800995 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengxuening and cyclosporin A (CsA)
Number of subjects: 45
Study 16800995 — intervention group
Group type: COMPARATOR
Intervention: Androgen alone
Number of subjects: 45
Study 14525815 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel
Number of subjects: 10
Study 14525815 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 10
Study 11093050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of plasma sCD26 and sCD30
Number of subjects: 0
Study 8841153 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (25 mg/16 hr) during sauna session
Number of subjects: 12
Study 8841153 — intervention group
Group type: COMPARATOR
Intervention: Control session (no sauna)
Number of subjects: 12
Study 1642129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 150 mg per day
Number of subjects: 46
Study 1642129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 6839004 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg single oral dose)
Number of subjects: 6
Study 6839004 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg single oral dose)
Number of subjects: 6
Study 31558376 — intervention group
Group type: COMPARATOR
Intervention: Single dose of ivermectin 200 μg/kg
Number of subjects: 309
Study 31558376 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of ivermectin 200 μg/kg (given on days 1, 2, 15, and 16)
Number of subjects: 309
Study 29314659 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-layer polyurethane foam dressing (ALLEVYN LIFE™)
Number of subjects: 359
Study 29314659 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 359
Study 26854246 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg daily)
Number of subjects: 53
Study 26854246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24280344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) for 6 months
Number of subjects: 30
Study 22880097 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 30
Study 22880097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 30
Study 20956902 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg midazolam with 0.5% hyperbaric bupivacaine
Number of subjects: 60
Study 20956902 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine with 5% dextrose in aqua
Number of subjects: 60
Study 17959979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 1305
Study 17959979 — intervention group
Group type: COMPARATOR
Intervention: Morphine IV PCA
Number of subjects: 1305
Study 16277588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and chemical oral cleansing using povidone-iodine
Number of subjects: 0
Study 16277588 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC) administered by dental hygienists once a week for 24 months
Number of subjects: 0
Study 16277588 — intervention group
Group type: EXPERIMENTAL
Intervention: POHC treatment for 6 months in the winter season
Number of subjects: 0
Study 16406170 — intervention group
Group type: EXPERIMENTAL
Intervention: HPIV3cp45 vaccine
Number of subjects: 80
Study 16406170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10828084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH (1 U daily)
Number of subjects: 24
Study 10828084 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH (2 U daily)
Number of subjects: 24
Study 10828084 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH (after 12 months)
Number of subjects: 24
Study 10828084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8657857 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy with relaxation therapy and autogenic training
Number of subjects: 42
Study 8657857 — intervention group
Group type: COMPARATOR
Intervention: Group therapy with relaxation therapy and autogenic training
Number of subjects: 42
Study 1505610 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-hour nicotine patch releasing 15 mg nicotine applied daily for 16 h over 12 weeks
Number of subjects: 167
Study 6345370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily
Number of subjects: 15
Study 6345370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg three times daily
Number of subjects: 15
Study 6345370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg three times daily
Number of subjects: 15
Study 6345370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29438562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (n = 1002)
Number of subjects: 1330
Study 29438562 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine (n = 328)
Number of subjects: 1330
Study 30242825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized salbutamol
Number of subjects: 50
Study 30242825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulized salbutamol
Number of subjects: 50
Study 26286298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (parents taught healthy lifestyles)
Number of subjects: 305
Study 26305442 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR) intervention administered to 97 participants in the experimental group.
Number of subjects: 211
Study 26305442 — intervention group
Group type: COMPARATOR
Intervention: Control group (114 participants) did not receive the CCR intervention.
Number of subjects: 211
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services with follow-up visit requirement
Number of subjects: 645
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services with lower infection rate
Number of subjects: 645
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services with less pain
Number of subjects: 645
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services with private waiting room
Number of subjects: 645
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services explaining risks and benefits
Number of subjects: 645
Study 22510052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based male circumcision services requiring an HIV test
Number of subjects: 645
Study 20118780 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin threshold of 7.0 g/dL)
Number of subjects: 124
Study 20118780 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin threshold of 9.5 g/dL)
Number of subjects: 124
Study 19094597 — intervention group
Group type: EXPERIMENTAL
Intervention: PHRAIC group
Number of subjects: 509
Study 19094597 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 509
Study 15925966 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute scapholunate dissociation (SLD) detected in patients with distal radius fractures
Number of subjects: 120
Study 15925966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic scapholunate dissociation (SLD)
Number of subjects: 120
Study 12401733 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E daily
Number of subjects: 3654
Study 12401733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3654
Study 10064663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg 4 times daily for 2 weeks)
Number of subjects: 95
Study 10064663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 2 weeks)
Number of subjects: 95
Study 10064663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 95
Study 10064663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 29873776 — intervention group
Group type: EXPERIMENTAL
Intervention: School lunch program (10 percentage point increase in coverage rate)
Number of subjects: 0
Study 29873776 — intervention group
Group type: EXPERIMENTAL
Intervention: School lunch program
Number of subjects: 0
Study 29273477 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb < 7.5 g/dL)
Number of subjects: 5000
Study 29273477 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb < 9.5 g/dL intraoperatively or postoperatively in ICU; Hb < 8.5 g/dL on the ward)
Number of subjects: 5000
Study 26272784 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress levels
Number of subjects: 2
Study 25493193 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tug lycosome formulation of dark chocolate (30 g daily)
Number of subjects: 29
Study 25493193 — intervention group
Group type: COMPARATOR
Intervention: Regular dark chocolate (30 g daily)
Number of subjects: 29
Study 25493193 — intervention group
Group type: COMPARATOR
Intervention: Dark chocolate with 7 mg of lycopene
Number of subjects: 29
Study 22516310 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200mg twice daily)
Number of subjects: 40
Study 22516310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19653741 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminous spot moving in the dark at varying speeds
Number of subjects: 0
Study 19653741 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in direction of successive motion vectors
Number of subjects: 0
Study 17589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 119
Study 17589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent
Number of subjects: 119
Study 17589978 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 119
Study 15206992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg 12 hourly for 7 days)
Number of subjects: 8
Study 15206992 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine alone
Number of subjects: 8
Study 11507213 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV recombinant canarypox vaccines
Number of subjects: 291
Study 9674400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly shaking and pinching the skin during lidocaine injection
Number of subjects: 103
Study 9674400 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 103
Study 8018904 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNU-VMP therapy
Number of subjects: 99
Study 8018904 — intervention group
Group type: COMPARATOR
Intervention: VMP therapy
Number of subjects: 99
Study 2659132 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim + sulphamethoxazole or mecillinam (Group A)
Number of subjects: 0
Study 2659132 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (Group B)
Number of subjects: 0
Study 2659132 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 0
Study 2659132 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B + C
Number of subjects: 0
Study 162677 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (150 mg daily)
Number of subjects: 0
Study 162677 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine with tranquillizer (perphenazine or diazepam)
Number of subjects: 0
Study 162677 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (15 mg daily)
Number of subjects: 0
Study 162677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31701698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 29
Study 31701698 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 29
Study 31403688 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging engagement with support persons
Number of subjects: 123
Study 31403688 — intervention group
Group type: COMPARATOR
Intervention: Participants who did not invite a support person
Number of subjects: 123
Study 29126292 — intervention group
Group type: EXPERIMENTAL
Intervention: ZVIN (4 doses)
Number of subjects: 351
Study 29126292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 25762120 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clips that elicited laughter and positive affect
Number of subjects: 0
Study 25762120 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 22767271 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored booster intervention
Number of subjects: 403
Study 22767271 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-term booster (67-94 days)
Number of subjects: 403
Study 22767271 — intervention group
Group type: COMPARATOR
Intervention: Control booster
Number of subjects: 403
Study 22767271 — intervention group
Group type: COMPARATOR
Intervention: No booster
Number of subjects: 403
Study 21703879 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill (AG) at 85% body weight
Number of subjects: 16
Study 21703879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AG treadmill)
Number of subjects: 16
Study 21703879 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AG and control groups
Number of subjects: 16
Study 18972832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation
Number of subjects: 24
Study 18972832 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 24
Study 18972832 — intervention group
Group type: COMPARATOR
Intervention: Non-administration (control)
Number of subjects: 24
Study 16801664 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcastle Mitochondrial Disease Adult Scale
Number of subjects: 0
Study 12707557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 432
Study 12707557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 432
Study 12707557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive-behavioral therapy
Number of subjects: 432
Study 12707557 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 432
Study 11055000 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative radiofrequency ablation in patients over 70 years (Group II)
Number of subjects: 178
Study 11055000 — intervention group
Group type: COMPARATOR
Intervention: Curative radiofrequency ablation in patients under 70 years (Group I)
Number of subjects: 178
Study 8648982 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements at the retina
Number of subjects: 10
Study 8648982 — intervention group
Group type: COMPARATOR
Intervention: Measurements at the pupil
Number of subjects: 10
Study 8648982 — intervention group
Group type: EXPERIMENTAL
Intervention: Observations at the retina for small bubbles up to 4 dd above the disc
Number of subjects: 10
Study 1534422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg or 800 mg single oral dose)
Number of subjects: 187
Study 1534422 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg single intramuscular dose)
Number of subjects: 187
Study 1534422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 187
Study 1534422 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 187
Study 6378988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg q.i.d. per os)
Number of subjects: 20
Study 6378988 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg b.i.d. per os)
Number of subjects: 20
Study 28948440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG infusion prior to embryo transfer (ET)
Number of subjects: 458
Study 28948440 — intervention group
Group type: COMPARATOR
Intervention: No hCG infusion prior to embryo transfer (ET)
Number of subjects: 458
Study 26681752 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 126
Study 26681752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (atorvastatin/niacin)
Number of subjects: 126
Study 26681752 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy (Atorvastatin)
Number of subjects: 126
Study 24375159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times daily for 2 months
Number of subjects: 40
Study 24375159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets/day) for 2 months
Number of subjects: 40
Study 23006975 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured brief advice and referral for a 20-minute motivational interviewing session with an alcohol health worker
Number of subjects: 120
Study 23006975 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 120
Study 20668668 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 (5x10^9 CFU)
Number of subjects: 151